Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

Bone Marrow Morphologic Features in Polycythemia Vera WithJAK2Exon 12 Mutations

(2010) Meredith A. Lakey et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

LNKMutations inJAK2Mutation–Negative Erythrocytosis

(2010) Terra L. Lasho et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients

(2010) Valerie Ugo et al.   PLoS One

Advances in Understanding and Management of Myeloproliferative Neoplasms

(2009) A. M. Vannucchi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera

(2009) S. Schnittger et al.   HAEMATOLOGICA

The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

(2009) D Olcaydu et al.   LEUKEMIA

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

(2009) Outi Kilpivaara et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

(2008) S. Li et al.   BLOOD

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

(2008) F. Passamonti et al.   BLOOD

Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis

(2008) A. V. Jones et al.   HAEMATOLOGICA